Evaluation of the Role of -137G/C Single Nucleotide Polymorphism (rs187238) and Gene Expression Levels of the IL-18 in Patients with Coronary Artery Disease

Overview

Journal Oman Med J

Specialty General Medicine

Date 2018 Apr 17

PMID 29657680

Citations 4

Authors

Fatemeh Hoseini

Sanaz Mahmazi

Khalil Mahmoodi

Gholam Ali Jafari

Mohammad Soleiman Soltanpour

Affiliations

Soon will be listed here.

Abstract

Objectives: Interleukin-18 (IL-18) is a proinflammatory and proatherogenic cytokine, and its genetic variations may contribute to the development of coronary artery disease (CAD). We sought to investigate the role of -137G/C polymorphism and gene expression levels of IL-18 in patients with CAD.

Methods: The study population included 100 patients with angiographically proven CAD and 100 matched controls. Total RNA and DNA were extracted from leukocytes using appropriate kits. The genotype of -137G/C polymorphism and gene expression level of IL-18 was determined using allele-specific polymerase chain reaction (PCR) and real-time (RT)-PCR assay, respectively.

Results: The genotypic and allelic distribution of IL-18 -137G/C polymorphism was not significantly different between the two groups ( > 0.050). Moreover, the -137G/C polymorphism did not increase the risk of CAD in dominant and recessive genetic models ( > 0.050). However, subgroup analysis of CAD patients revealed that the IL-18 -137G/C polymorphism was significantly associated with increased risk of CAD in hypertensive patients (odds ratio (OR) = 7.51; 95% confidence interval (CI): 1.24-25.17; 0.019) and smokers (OR = 4.90; 95% CI: 1.21-19.70; 0.031) but not in the diabetic subpopulation ( 0.261). The genotype distribution of IL-18 -137G/C genetic polymorphism was significantly different among patients with one, two, and three stenotic vessels ( < 0.050). The gene expression level of IL-18 was significantly higher in the CAD group than the control group ( < 0.001). Moreover, the carriers of CC genotype had significantly lower gene expression levels of IL-18 than carriers of GG genotype ( < 0.050).

Conclusions: The -137G/C polymorphism of IL-18 may be associated with the CAD risk in hypertensive and smoker subgroup of CAD patients. The -137G/C polymorphism seems to play an important role in determining the severity of CAD. Increased IL-18 gene expression level is a significant risk factor for the development of CAD. The CC genotype of -137G/C polymorphism is associated with lower IL-18 gene expression levels.

Citing Articles

Cytokine Gene Variants as Predisposing Factors for the Development and Progression of Coronary Artery Disease: A Systematic Review.

Li F, Zhang Y, Wang Y, Cai X, Fan X Biomolecules. 2025; 14(12.

PMID: 39766338 PMC: 11726869. DOI: 10.3390/biom14121631.

Polymorphisms of Pro-Inflammatory IL-6 and IL-1β Cytokines in Ascending Aortic Aneurysms as Genetic Modifiers and Predictive and Prognostic Biomarkers.

Scola L, Giarratana R, Marinello V, Cancila V, Pisano C, Ruvolo G Biomolecules. 2021; 11(7).

PMID: 34202072 PMC: 8301826. DOI: 10.3390/biom11070943.

IL-35 polymorphisms and cognitive decline did not show any association in patients with coronary heart disease over a 2-year period: A retrospective observational study (STROBE compliant).

Shi Y, Zhang S, Xue Y, Yang Z, Lin Y, Liu L Medicine (Baltimore). 2020; 99(31):e21390.

PMID: 32756130 PMC: 7402886. DOI: 10.1097/MD.0000000000021390.

No association between interleukin-18 levels and risk of cardiovascular disease: A Mendelian randomization study.

Fan S, He P, Guan J, Song W, Zhi H, Wang L Hereditas. 2020; 157(1):12.

PMID: 32264954 PMC: 7140355. DOI: 10.1186/s41065-020-00121-5.

Association between polymorphisms in interleukin-18 promoter and risk of coronary artery disease: a meta-analysis.

Lian Z, Li S, Cui Y, Wu M, Su L, Hu D Biosci Rep. 2019; 39(11).

PMID: 31661113 PMC: 6863765. DOI: 10.1042/BSR20192721.

References

Liu W, Tang Q, Jiang H, Ding X, Liu Y, Zhu R . Promoter polymorphism of interleukin-18 in angiographically proven coronary artery disease. Angiology. 2008; 60(2):180-5. DOI: 10.1177/0003319708319939. View

Dai X, Wiernek S, Evans J, Runge M . Genetics of coronary artery disease and myocardial infarction. World J Cardiol. 2016; 8(1):1-23. PMC: 4728103. DOI: 10.4330/wjc.v8.i1.1. View

Ansari W, Humphries S, Naveed A, Khan O, Khan D . Influence of cytokine gene polymorphisms on proinflammatory/anti-inflammatory cytokine imbalance in premature coronary artery disease. Postgrad Med J. 2016; 93(1098):209-214. DOI: 10.1136/postgradmedj-2016-134167. View

Ammirati E, Moroni F, Magnoni M, Camici P . The role of T and B cells in human atherosclerosis and atherothrombosis. Clin Exp Immunol. 2014; 179(2):173-87. PMC: 4298395. DOI: 10.1111/cei.12477. View

Dziedziejko V, Kurzawski M, Paczkowska E, Machalinski B, Pawlik A . The impact of IL18 gene polymorphisms on mRNA levels and interleukin-18 release by peripheral blood mononuclear cells. Postepy Hig Med Dosw (Online). 2012; 66:409-14. DOI: 10.5604/17322693.1000980. View

Pieris R, Al-Sabti H, Al-Abri Q, Rizvi S . Prevalence Pattern of Risk Factors for Coronary Artery Disease among Patients Presenting for Coronary Artery Bypass Grafting in Oman. Oman Med J. 2014; 29(3):203-7. PMC: 4052385. DOI: 10.5001/omj.2014.50. View

Dezayee Z . Interleukin-18 can predict pre-clinical atherosclerosis and poor glycemic control in type 2 diabetes mellitus. Int J Appl Basic Med Res. 2013; 1(2):109-12. PMC: 3657961. DOI: 10.4103/2229-516X.91155. View

Graebe M, Pedersen S, Borgwardt L, Hojgaard L, Sillesen H, Kjaer A . Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg. 2008; 37(6):714-21. DOI: 10.1016/j.ejvs.2008.11.018. View

Evans J, Collins M, Jennings C, van der Merwe L, Soderstrom I, Olsson T . The association of interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease. Eur J Endocrinol. 2007; 157(5):633-40. DOI: 10.1530/EJE-07-0463. View

10.

Galkina E, Ley K . Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009; 27:165-97. PMC: 2734407. DOI: 10.1146/annurev.immunol.021908.132620. View

11.

Giedraitis V, He B, Huang W, Hillert J . Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol. 2000; 112(1-2):146-52. DOI: 10.1016/s0165-5728(00)00407-0. View

12.

Jefferis B, Papacosta O, Owen C, Wannamethee S, Humphries S, Woodward M . Interleukin 18 and coronary heart disease: prospective study and systematic review. Atherosclerosis. 2011; 217(1):227-33. PMC: 3146704. DOI: 10.1016/j.atherosclerosis.2011.03.015. View

13.

Jain S, Shah M, Li Y, Vinukonda G, Sehgal P, Kumar A . Upregulation of human angiotensinogen (AGT) gene transcription by interferon-gamma: involvement of the STAT1-binding motif in the AGT promoter. Biochim Biophys Acta. 2006; 1759(7):340-7. DOI: 10.1016/j.bbaexp.2006.07.003. View

14.

Turner M, Nedjai B, Hurst T, Pennington D . Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta. 2014; 1843(11):2563-2582. DOI: 10.1016/j.bbamcr.2014.05.014. View

15.

Sayols-Baixeras S, Lluis-Ganella C, Lucas G, Elosua R . Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants. Appl Clin Genet. 2014; 7:15-32. PMC: 3920464. DOI: 10.2147/TACG.S35301. View

16.

Ramji D, Davies T . Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev. 2015; 26(6):673-85. PMC: 4671520. DOI: 10.1016/j.cytogfr.2015.04.003. View

17.

Al Rawahi A, Lee P, Al Anqoudi Z, Al Busaidi A, Al Rabaani M, Al Mahrouqi F . Cardiovascular Disease Incidence and Risk Factor Patterns among Omanis with Type 2 Diabetes: A Retrospective Cohort Study. Oman Med J. 2017; 32(2):106-114. PMC: 5397087. DOI: 10.5001/omj.2017.20. View

18.

Zhu S, Zhao Y, Hu X, Luo T, Chen Z, Zhang Y . Genetic polymorphisms -137 (rs187238) and -607 (rs1946518) in the interleukin-18 promoter may not be associated with development of hepatocellular carcinoma. Sci Rep. 2016; 6:39404. PMC: 5175127. DOI: 10.1038/srep39404. View

19.

Kariz S, Petrovic D . Interleukin-18 Promoter Gene Polymorphisms are not Associated with Myocardial Infarction in Type 2 Diabetes in Slovenia. Balkan J Med Genet. 2013; 14(1):3-9. PMC: 3776693. DOI: 10.2478/v10034-011-0011-6. View

20.

Hernesniemi J, Karhunen P, Oksala N, Kahonen M, Levula M, Rontu R . Interleukin 18 gene promoter polymorphism: a link between hypertension and pre-hospital sudden cardiac death: the Helsinki Sudden Death Study. Eur Heart J. 2009; 30(23):2939-46. DOI: 10.1093/eurheartj/ehp316. View